Highmark and UCB Partner on Outcomes-based Contract for CIMZIA
Highmark has entered an outcomes-based agreement with UCB, Inc. for CIMZIA® (certolizumab pegol), UCB’s tumor necrosis factor blocker prescribed for [...]
Advertisement
Highmark has entered an outcomes-based agreement with UCB, Inc. for CIMZIA® (certolizumab pegol), UCB’s tumor necrosis factor blocker prescribed for [...]
